AstraZeneca and Johnson & Johnson vaccines are apparently not the only COVID-19 pharmaceutical products found to cause hypercoagulability: A 16-year-old boy in Israel developed hypercoagulability and had to undergo emergency clot removal surgery after receiving the Pfizer COVID-19 vaccine.
The Wall Street Journal last week reported that Johnson & Johnson privately reached out to COVID-19 vaccine rivals to ask them to join an effort to study the risks of blood clots and speak with one voice about safety, but Pfizer and Moderna “declined”.
Health Communication Lecturer at IDC Herzliya International School Dr. Yaffa Shir Raz responded to the incident, saying: “Think hard before you offer up your kids.”
